Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L SILBERSTEIN

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2024
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and functionJohn L Silberstein, Jasper Du, Kun-Wei Chan, et al.
Oncogene|August 15, 2019
Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancerSubing Cao, Tianfang Ma, Nathan Ungerleider, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
European Urology|September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerYezi Zhu, Adam Sharp, Courtney M Anderson, et al.
Oncotarget|February 3, 2017
Detection fidelity of AR mutations in plasma derived cell-free DNAAlexa Goldstein, Patricia Valda Toro, Justin Lee, et al.
JCO Precision Oncology|May 28, 2019
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate CancerSamantha Torquato, Aparna Pallavajjala, Alexa Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Science Translational Medicine|August 5, 2011
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSAScott A Tomlins, Sheila M J Aubin, Javed Siddiqui, et al.
Nature Medicine|January 14, 2022
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradicationJohanna Theruvath, Marie Menard, Benjamin A H Smith, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2024
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and functionJohn L Silberstein, Jasper Du, Kun-Wei Chan, et al.
Oncogene|August 15, 2019
Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancerSubing Cao, Tianfang Ma, Nathan Ungerleider, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
European Urology|September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerYezi Zhu, Adam Sharp, Courtney M Anderson, et al.
Oncotarget|February 3, 2017
Detection fidelity of AR mutations in plasma derived cell-free DNAAlexa Goldstein, Patricia Valda Toro, Justin Lee, et al.
JCO Precision Oncology|May 28, 2019
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate CancerSamantha Torquato, Aparna Pallavajjala, Alexa Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Science Translational Medicine|August 5, 2011
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSAScott A Tomlins, Sheila M J Aubin, Javed Siddiqui, et al.
Nature Medicine|January 14, 2022
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradicationJohanna Theruvath, Marie Menard, Benjamin A H Smith, et al.
Pageof 14